Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with stage II or III locally advanced rectal cancer that is MSI-high or mismatch repair deficient (dMMR), confirmed using an FDA-authorized solid-tumor test.
SUPPORTING DATA
Evidence behind the decision
- Study
- AZUR-1 treated 154 previously untreated patients in an open-label, single-arm study. FDA also reviewed a separate investigator-led study.
- Key result
- In AZUR-1, 47% of 116 participants evaluable by independent central review sustained a clinical complete response for 12 months. The separate investigator-led study reported 93% in 50 participants.
- Safety to report
- FDA labeling includes immune-mediated and infusion reactions and complications of allogeneic stem-cell transplantation.
- Evidence limits
- The studies used different cohorts and assessments. Avoid treating a complete clinical response as a cure or comparing the rates head to head.
LAMPGEN ANALYSIS
Why it matters
The decision opens an immunotherapy option for a molecularly defined rectal cancer population. The possibility of organ preservation depends on sustained response and access to close follow-up.
What research teams should watch
Nonoperative follow-up requires coordination across endoscopy, rectal MRI, oncology and surgery. Sites need a plan for missed surveillance visits and for rapid review of possible recurrence.
PRIMARY RECORDS